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Background:  Two  main  shortcomings  of  classical  allergen-speciﬁc  immunotherapy  are  long  treatment
duration  and  low  patient  compliance.  Utilizing  the  unique  immunological  features  of  the  skin  by  tran-
scutaneous  application  of  antigen  opens  new  approaches  not  only  for painless  vaccine  delivery, but  also
for  allergen-speciﬁc  immunotherapy.  Under certain  conditions,  however,  barrier  disruption  of  the skin
favors T  helper  2-biased  immune  responses,  which  may  lead  to new  sensitizations.
Methods:  In a  prophylactic  approach,  an infra-red  laser  device  was employed,  producing  an  array  of
micropores  of user-deﬁned  number,  density,  and  depth  on  dorsal  mouse  skin.  The grass  pollen  allergen
Phl  p  5 was  administered  by  patch  with  or without  the  T  helper  1-promoting  CpG  oligodeoxynucleotide
1826 as  adjuvant,  or was  subcutaneously  injected.  Protection  from  allergic  immune  responses  was  tested
by sensitization  via  injection  of  allergen  adjuvanted  with  alum,  followed  by intranasal  instillation.  In  a
therapeutic  setting,  pre-sensitized  mice  were  treated  either  by the  standard  method  using subcutaneous
injection  or  via  laser-generated  micropores.  Sera  were  analyzed  for IgG antibody  subclass  distribution  by
ELISA and for  IgE antibodies  by  a basophil  mediator  release  assay.  Cytokine  proﬁles  from  supernatants
of  re-stimulated  lymphocytes  and  from  bronchoalveolar  lavage  ﬂuids  were  assessed  by ﬂow  cytometry
using  a bead-based  assay.  The  cellular  composition  of  lavage  ﬂuids  was  determined  by ﬂow  cytometry.
Results:  Application  of  antigen  via  micropores  induced  T helper  2-biased  immune  responses.  Addition  of
CpG  balanced  the response  and prevented  from  allergic  sensitization,  i.e. IgE induction,  airway  inﬂam-
mation,  and  expression  of  T helper  2 cytokines.  Therapeutic  efﬁcacy  of  transcutaneous  immunotherapy
was  equal  compared  to  subcutaneous  injection,  but was  superior  with  respect  to  suppression  of  already
established  IgE responses.
Conclusions: Transcutaneous  immunotherapy  via  laser-generated  micropores  provides  an  efﬁcient  novel
platform  for  treatment  of  type I allergic  diseases.  Furthermore,  immunomodulation  with  T helper  1-
promoting  adjuvants  can  prevent  the risk  for  new  sensitization.
 . Introduction
Effective allergen-speciﬁc immunotherapy (SIT), regardless if
erformed by subcutaneous injections (SCIT) or sublingual applica-
ion using droplets or tablets (SLIT), is perceived as an intervention
o redirect inappropriate and exaggerated TH2 responses against
Abbreviations: SIT, Allergen-speciﬁc immunotherapy; Th, T helper; SCIT,
ubcutaneous allergen-speciﬁc immunotherapy; SLIT, Sublingual allergen-speciﬁc
mmunotherapy; P.L.E.A.S.E.® , Precise laser epidermal system; TCIT, Transcutaneous
llergen-speciﬁc immunotherapy; TCI, Transcutaneous immunization; BAL, Bron-
hoalveolar lavage; BALF, Bronchoalveolar lavage ﬂuid.
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allergens. Crucial events for this immune deviation are the prefer-
ential production of TH1 cytokines such as IFN-, and the induction
of IL-10/TGF- secretion by T regulatory cells in blood and inﬂamed
airways [1]. Furthermore, suppression of allergen-speciﬁc IgE and
induction of IgG4, and suppression of mast cells, basophils, and
eosinophils contribute to the control of allergen-speciﬁc immune
responses associated with SIT [2]. Despite its veriﬁable clinical suc-
cess [3,4], only a small percentage of patients prefer this therapy to
symptomatic treatment [5,6], and drop-out rates are considerable
[7,8], mainly due to therapy duration of 3-5 years and local (SLIT)
and/or systemic (SCIT) side effects [9,10]. The ideal SIT approach
Open access under CC BY-NC-ND license.should therefore (i) target a tissue rich in immunocompetent cells
to increase efﬁcacy, thereby reducing the number of required doses,
(ii) employ a needle-free administration method, and (iii) avoid
contact with the circulation to minimize the risk of systemic side
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ffects. Cutaneous delivery perfectly fulﬁlls these prerequisites
s the skin is easily accessible, harbors high numbers of anti-
en presenting cells, provides non-vascularized superﬁcial layers,
nd delivery techniques avoiding needle and syringe have become
vailable. In our current study, we used one of these platforms, the
.L.E.A.S.E® (Precise Laser Epidermal System) device for fractional
blation of superﬁcial skin layers and the creation of micropo-
es. This novel technology employs a diode-pumped Er:YAG laser,
hich emits light at 2.94 m,  corresponding to a major absorption
eak of water molecules. Their excitation and evaporation leads
o formation of aqueous micropores with a diameter of approx.
50 m.  Due to extremely short energy pulses, heat transfer to
eighboring tissue is negligible. Using a scanning laser technology,
n array of several hundred identical micropores of pre-deﬁned
umber, density and depth can be sequentially created within a
ew seconds. In contrast to other transcutaneous vaccination meth-
ds, the P.L.E.A.S.E® laserporation system is easily adaptable to
arget appropriate skin layers in different species/individuals by
djusting the number of pulses per pore. Originally intended for
ncreased delivery of small molecular weight compounds [11–13],
n vivo transport of functionally intact proteins, such as antibodies,
ia P.L.E.A.S.E® -generated micropores has also been demonstrated
14].
Epicutaneous immunotherapy performed by application of
llergen extracts to an area at the volar forearm, which had been
re-treated by needle scariﬁcation, was already described more
han 50 years ago [15]. Recently, studies in mice and humans
evisited this approach replacing needle scariﬁcation by adhesive
ape stripping [16,17] or application of an occlusive chamber to
ncrease skin permeability by hydration [18,19]. However, epicuta-
eous immunization on barrier-disrupted skin has been linked with
he induction of TH2-biased responses [20,21], and sensitization to
llergens [22,23]. Similarly, we also found that cutaneous deliv-
ry of different antigens via laser-generated micropores can lead
o the generation of TH2-driven immunity[24]. Triggering of this
mmune response type would render transcutaneous immunother-
py (TCIT) problematic for treatment of type I allergy. Especially
hen using poorly deﬁned allergen extracts, even a minimal risk for
ew sensitizations against previously unrecognized components
as to be avoided. Therefore, the use of proper adjuvants, which
an suppress TH2 responses in the skin, has to be considered. It
as been previously shown that topical application of adjuvant to
he site of vaccination leads to activation and migration of antigen
resenting cells to skin draining lymph nodes [25]. In our present
ork we used a major timothy grass pollen allergen adjuvanted
ith CpG oligodeoxynucleotides (ODN) 1826, which are known
or their TH1-promoting immunomodulatory capacity [26]. Fur-
hermore, we compared the efﬁcacy of TCIT with subcutaneous
njection, which is the standard application in SIT.
. Materials and methods
.1. Animals
BALB/c females, aged 6-8 weeks, were purchased from Charles
iver Laboratories (Sulzfeld, Germany) and maintained at the ani-
al  facility of the University of Salzburg. All animal experiments
ere conducted according to local guidelines approved by the
ustrian Ministry of Science (Permit Number: GZ 66.012/0004-
I/10b/2010), and in accordance with EU Directive 2010/63/EU..2. Laser microporation
The day before laser microporation, mice were shaved on
heir back with a clipper, and depilatory cream was used toe 31 (2013) 3427– 3434
remove residual hair keeping the animals under inhalational
anesthesia with isoﬂurane. Micropores were generated using the
P.L.E.A.S.E.® device (Pantec Biosolutions AG, Ruggell, Liechten-
stein) by placing mice, anesthetized by intraperitoneal injection
of ketamine/xylazine (80 mg  ketamine, 7.5 mg  xylazine per kg
body weight), with their back at the focal length of the laser.
Laser parameters, i.e. number of pores/cm2, number of pulses
per pore, and ﬂuence (energy applied per unit area) were pre-
programmed using the device software. For vaccination as well
as immunotherapy, 4 pulses with a ﬂuence of 1.9 J/cm2 per pulse
were applied, and 500 pores/cm2 (circular area, 1 cm diameter)
were generated. With these settings a pore depth of approxi-
mately 30-40 m penetrating well into the dermis was achieved,
as previously described [24]. Antigen with or without adjuvant was
applied by a patch consisting of a 10 mm  × 10 mm  piece of gauze
(Aluderm®, W.  Soehngen, Taunusstein-Wehen, Germany) soaked
with the antigen solution and an adhesive tape (OpSite Flexiﬁx,
Smith&Nephew, Schenefeld, Germany). The patch was removed
after 24 h.
2.3. Vaccination
Immunizations were performed twice (day 0 and day 10) by
application of 10 g recombinant Phl p 5 (Biomay AG, Vienna,
Austria) in 80 L PBS, with or without additional 100 g CpG
ODN 1826 (Biomers, West-Ulm, Germany), onto a single laserpo-
rated skin area, or by s.c. injection of the same amount of antigen
with or without adjuvant. Starting on day 28, immunized ani-
mals (5 animals per group) and untreated controls (n = 5) were
sensitized by two  intraperitoneal injections with 1 g Phl p 5
in 100 L PBS adjuvanted with 100 L Al(OH)3, followed by 3
intranasal instillations on 3 consecutive days of 1 g Phl p 5 in
40 L PBS. On day 54, animals were sacriﬁced and bronchoalve-
olar lavages (BALs) were performed. Blood samples were drawn on
days 17 and 53. A detailed experimental schedule is presented in
Fig. 1A.
2.4. Speciﬁc immunotherapy
For therapy, mice were sensitized twice within 10 days by
intraperitoneal injections with 1 g Phl p 5 in 100 L PBS adju-
vanted with 100 L Al(OH)3, followed by two series of 3 intranasal
instillations on 3 consecutive days of 1 g Phl p 5 in 40 L
PBS. Speciﬁc immunotherapy was  performed twice a week for
three weeks with 50 g recombinant Phl p 5 adjuvanted with
100 g CpG ODN, applied as skin patch onto microporated
skin areas (one non-overlapping area per treatment) or by s.c.
injection (7 animals per group). Control animals (n = 6) were
left untreated. Mice were challenged with another 2 series of
intranasal instillations, and sacriﬁced on day 90. Blood samples
were collected on days 41 (after sensitization), and 80 (after
therapy). An overview of the experimental schedule is given in
Fig. 4A.
2.5. Serology and cytokines
Sera were analysed for Phl p 5-speciﬁc IgG1 and IgG2a
by a luminescence-based ELISA at indicated serum dilutions
lying within the linear range of the assay. Biologically func-
tional IgE was  determined by an in vitro basophil release assay
as described [27]. Brieﬂy, rat basophil leukemia cells (RBL-
2H3) were incubated with sera at indicated dilutions for 2 h
followed by addition of recombinant allergen, leading to cross-
linking of FcR-bound IgE and mediator release from the cells.
Beta-hexosaminidase in supernatants thereof was determined
by addition of 4-MUG, a substrate forming stable complexes
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Fig. 1. Prophylactic vaccination. (A) BALB/c mice (n = 5) were vaccinated transcutaneously via laser-generated micropores (TCI) or by subcutaneous injection (SC) with or
without CpG ODN (“vaccination”), or with CpG ODN alone (CpG; applied transcutaneously) and subsequently sensitized by intraperitoneal injection of alum-adsorbed allergen
(“sensitization”), followed by intranasal allergen challenge (“i.n.”). Non pre-vaccinated, but sensitized animals (“control”) and naïve animals served as controls. (B) Serum
samples post vaccination and post sensitization were analyzed for allergen-speciﬁc IgG1, IgG2a, and IgE by ELISA or RBL release assay at the indicated serum dilutions. Data
are  shown as means ± SEM or individual data points. ELISA data are shown as relative light units (RLU) and RBL data as percentage of maximal release (% release). **P < 0.01.
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Cost-vaccination data of panel 1B has been previously published [24].
ith the enzyme, which can be detected by ﬂuorescence spec-
roscopy (ex360 nm/em465 nm). Splenocytes were cultured in
he presence or absence of 10 g/mL recombinant Phl p 5 for 3
ays and cytokine proﬁles in supernatants thereof were assessed
ia mouse TH1/TH2/TH17/TH22 13plex FlowCytomix multiplex
it combined with the mouse GM-CSF FlowCytomix simplex
it (eBioscience, San Diego, USA) according to the manufac-
urer’s instructions. Additionally, TGF-1 was measured using a
uman/mouse TGF-1 ELISA Ready-SET-Go! kit (eBioscience, San
iego, USA).
.6. Analysis of bronchoalveolar lavagesAt the end of the experimental schedule, animals were
acriﬁced and bronchoalveolar lavages were performed as
escribed [28]. Cells were stained with CD45-FITC, CD4-APC/Cy7,
D19-PE, Gr1-APC (Biolegend or eBioscience, San Diego USA).Eosinophils were distinguished from other leukocyte popu-
lations by their CD45med Gr1low side-scatterhigh phenotype.
Cytokine proﬁles of lavage ﬂuids were established using the
mouse TH1/TH2/TH17/TH22 13plex FlowCytomix multiplex kit
(eBioscience, San Diego, USA). Neutrophil derived peroxidase
activity in BALF was  determined by mixing 50 L of BALF
with 50 L of BM Chemiluminescence ELISA Substrate (POD)
(Roche, Basel, Switzerland) and measuring the resulting lumi-
nescence on an Inﬁnite 200 PRO reader (Tecan, Männedorf,
Switzerland).
3. Statistical analysisStatistical signiﬁcance between groups was assessed by
unpaired Student’s t-test (alpha = .05) using SigmaStat 2.0. Groups
that failed normality test were compared using Mann-Whitney
rank sum test. Multiple comparisons of serum titrations were
3430 M. Hessenberger et al. / Vaccine 31 (2013) 3427– 3434
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Tig. 2. Cytokine proﬁle of pre-vaccinated animals. Cytokine production of splenocyt
f  IL-4-secreting cells was determined by ELISPOT (A) and IL-5, IL-13, IL-2, and 
eans  ± SEM (n = 5; CpG only group: n = 4) or individual data points. *P < 0.05, **P <
erformed by two-tailed ANOVA as indicated in the text.
orrelation analysis was done using Spearman’s Rank Correla-
ion.
. Results and discussion
.1. Effects of transcutaneous immunization on subsequent
ensitization to allergens
We previously found that similar to other methods of cuta-
eous antigen delivery, transcutaneous immunization (TCI) via
aser-generated micropores can lead to induction of a TH2-biased
erological proﬁle including the secretion of IgE and generation of
L-4 secreting TH2 cells, both of which can be suppressed by the
ddition of TLR agonists including CpG ODN[24]. In a ﬁrst set of
xperiments employing the major timothy grass pollen allergen
hl p 5, we investigated the effect of TCI with and without CpG
DN on the resulting immune response and its impact on subse-
uent allergic sensitization by alum-adsorbed protein followed by
irway provocation (see Fig. 1A for experimental schedule).
.1.1. CpG ODN prevent transcutaneous IgE induction and protect
rom subsequent alum-induced sensitization
As shown in Fig. 1B (post vaccination), TCI in the absence of
djuvant was more potent in inducing antigen speciﬁc IgG1 com-
ared to s.c. injection (P < 0.01; ANOVA) while no differences in
he IgG2a levels were observed. However, only TCI also induced
gE as measured by basophil release assay. This TH2 priming effect
ia the skin has been recently associated to stress-induced activa-
ion of dendritic epidermal T cells (DETC) and NKT cells producing
H2 promoting cytokines such as IL-13, IL-25, and IL-33 [29]. pre-vaccinated and control animals was analyzed after sensitization. The number
was measured in supernatants of re-stimulated splenocytes. Data are shown as
Skin barrier disruption also activates keratinocytes to secrete TSLP
which promotes survival, maturation, and migratory properties of
freshly isolated Langerhans cells and the production of pro-allergic
cytokine proﬁles in co-cultured CD4+ T cells [30]. High expression
of TSLP in keratinocytes has been found in patients with atopic
dermatitis, as well as in activated mast cells [31].
Addition of CpG ODN restored the IgG1 levels after s.c. injection
to the levels obtained by TCI and boosted IgG2a for both appli-
cation methods (P < 0.0001 vs. non-adjuvanted delivery; ANOVA)
and also completely suppressed IgE induction after TCI, conﬁrming
previous data demonstrating that CpG ODN can shift skin vaccina-
tion induced TH2 responses towards TH1 [32]. Moreover, addition
of CpG ODN during vaccination suppressed the subsequent sensi-
tization by alum-adsorbed allergen (Fig. 1B, post sensitization) in
an antigen speciﬁc manner (P < 0.01 vs. control; t-test). Although
pre-treatment with CpG alone (antigen unspeciﬁc) also induced
elevated levels of IgG2a after sensitization (P < 0.05 vs. control;
ANOVA), indicating the persistence of a TH1 modulating milieu at
the time-point of sensitization, this effect was  not sufﬁcient to pre-
vent the induction of allergen-speciﬁc IgE. Despite the induction of
IgE by TCI without adjuvant during the primary immune response,
IgE levels after sensitization were comparable to those observed in
the s.c. injected group.
4.1.2. CpG ODN are necessary for suppression of TH2 cytokines
but not IL-22
When evaluating the cytokine proﬁle of re-stimulated spleno-
cytes at the end of the experiment, we  found a clear suppression
of IL-4 (Fig. 2A), IL-5 (Fig. 2B), and IL-13 (Fig. 2C) by CpG adju-
vanted vaccination by either the transcutaneous or subcutaneous
route, although s.c. injection and TCI alone also (to a lesser degree)
M.  Hessenberger et al. / Vaccine 31 (2013) 3427– 3434 3431
Fig. 3. Lung inﬁltration of pre-vaccinated animals. The number of BAL inﬁltrating leukocytes in pre-vaccinated and control animals were analyzed after sensitization. The
number of total lymphocytes (A), eosinophils (B), neutrophils (C) per BAL are shown. Peroxidase activity in BALF is displayed as relative light units (D), and IL-5 (E) and IL-13
(F)  concentrations in BALF were measured by FlowCytomix assay. Data are shown as means ± SEM (n = 5; control group: n = 4) and individual data points. *P < 0.05, **P < 0.01,
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uppressed IL-13. Surprisingly, we found no induction of IFN- or
NF- (not shown), indicative of a TH1 response; on the contrary,
re-vaccination with or without CpG suppressed IL-2 (Fig. 2D) com-
ared to sensitization controls. Finally, s.c. injection suppressed
he TH17/TH22 cytokine IL-22 (Fig. 2E), which may  play a role
n the early onset of allergic lung inﬂammation [33] but also
as been implicated as immunosuppressive during early immune
esponses [34]. Although we could not detect IL-17, sensitization
ith alum-adsorbed allergen may  lead to inﬂammasome activa-ion and generation of IL-22 secreting TH17 cells [35]. Both, TH1 or
H2 responses primed by pre-vaccination could suppress the TH17
esponses [36] induced by the sensitization protocol and therefore
xplain the observed reduction in IL-22.4.1.3. Pre-vaccination prevents or exacerbates eosinophilic
inﬂammation of the airways depending on the presence of CpG
ODN
As shown in Fig. 3, transcutaneous and subcutaneous vaccina-
tion mildly elevated the number of BAL lymphocytes independent
of CpG co-administration (Fig. 3A), but only CpG ODN  adjuvanted
allergen abrogated sensitization induced BAL eosinophilia (Fig. 3B)
which correlated with reduced levels of IL-5 (Fig. 3E, P < 0.01; Spear-
man) and IL-13 (Fig. 3F, P < 0.0001; Spearman) in BALF. On the
contrary, pre-vaccination without adjuvant exacerbated inﬂamma-
tion as indicated by increased numbers of eosinophils and highly
elevated levels of IL-13. These data show that both, TCI as well as
s.c. injection of recombinant allergen into naïve animals can have a
3432 M. Hessenberger et al. / Vaccine 31 (2013) 3427– 3434
Fig. 4. Allergen-speciﬁc immunotherapy. (A) BALB/c mice (n = 7; control group: n = 6) were sensitized by intraperitoneal injection of alum-adsorbed allergen, followed by
intranasal allergen challenge (“sensitization”). Subsequently, animals were treated by transcutaneous immunotherapy via laser-generated micropores (TCIT) or subcutaneous
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elease  (% release). *P < 0.05, ***P < 0.001.
egative impact on later acquired allergic sensitization and this has
o be taken into consideration with regards to prophylactic vaccina-
ion strategies against allergy. In contrast to Haapakoski et al., CpG
DN co-administration did not induce enhanced levels of IFN- in
ALF (not shown) [37], but similar to Duechs et al. [38], we found
levated levels of BAL neutrophils (Fig. 3C) which were associated
ith increased levels of neutrophil derived peroxidase activity in
ALF (Fig. 3D). However, at least with a protective approach using
NA vaccines, we previously found that this increase in neutrophils
n vaccinated mice is only present during the acute phase of lung
nﬂammation, while after repeated airway exposures, the levels of
eutrophils return to baseline while protection from eosinophila is
aintained (unpublished observations).
.2. Transcutaneous immunotherapy of allergy is equally efﬁcient
ompared to standard SCIT
As our previous data indicated that both, s.c. as well as tran-
cutaneous application of allergen in a prophylactic setting mayi.n.). (B) Allergen-speciﬁc serum IgG1, IgG2a, and IgE was assessed before and after
 data are shown as relative light units (RLU) and RBL data as percentage of maximal
have detrimental side effects in the absence of a TH2 blocking adju-
vant, we next investigated a CpG-adjuvanted therapeutic approach,
comparing the transcutaneous with the subcutaneous route. For
that purpose, mice were sensitized and airway inﬂammation was
induced, followed by a therapeutic intervention and a ﬁnal re-
challenge via the airways. The experimental schedule is shown in
Fig. 4A. Before the start of the therapy, IgG1, IgG2a (Fig. 4B – top
panel), and IgE levels (Fig. 4B – bottom right panel) were similar in
all groups.
4.2.1. TCIT, but not SCIT, shifts the serological proﬁle towards TH1
and suppresses established IgE responses
TCIT and SCIT with CpG-adjuvanted allergen signiﬁcantly
increased the levels of IgG1, but only TCIT also elevated IgG2a,
indicating a shift towards TH1 at least on the serological level.
This is in accordance with the observation that only TCIT signif-
icantly reduced allergen-speciﬁc IgE (Fig. 4B). However, cytokine
responses of in vitro re-stimulated splenocytes showed a stronger
reduction of TH2 (IL-4, IL-5, IL-13), TH1 (IL-2, IFN-) and TH17
M.  Hessenberger et al. / Vaccine 31 (2013) 3427– 3434 3433
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nig. 5. Splenic cytokine proﬁle after speciﬁc immunotherapy. Cytokine levels were
re  shown as means ± SEM (n = 7; control group: n = 6) or individual data points. *P 
IL-22) cytokines after SCIT (Fig. 5). As IFN- is the pivotal switch
actor for IgG2a, the lack of IFN- (and the modest suppression
f TH2/TH17 cytokines) suggests, that TCIT induced TH1 cells are
ither short-lived and no longer present, or more likely do not
rimarily home into the spleen but to the skin. Recent ﬁndings
mplicating the importance of locally residing effector memory T
ells after skin immunization have been reviewed in [39].
.2.2. Speciﬁc immunotherapy successfully downregulates
stablished inﬂammation of the lung
As demonstrated in Fig. 6, TCIT downregulates the numbers of
nﬁltrating cells in BALF. Compared to the untreated control ani-
als, TCIT signiﬁcantly reduced the number of CD4+ T-cells, CD19+
-cells, as well as eosinophils. In contrast to the acute inﬂammation
een in the prophylactic situation (Fig. 3C), in the therapeutic set-
ing CpG-adjuvanted immunotherapy did not increase the number
f neutrophils in the lung, but on the contrary, TCIT even signiﬁ-
antly decreased them. Therapeutic efﬁcacy of TCIT at least equaled
hat of SCIT and was independent of the inﬂux of CD4 + CD25+ reg-
latory T cells into the lung, as their percentage of total CD4+ cells
ig. 6. Effect of speciﬁc immunotherapy on lung inﬁltration. After an intranasal re-
hallenge (post therapy), BAL inﬁltrating leukocytes were assessed. The numbers of
ifferent leukocyte subsets per BAL are shown as means ± SEM (n = 7; control group:
 = 6). *P < 0.05, **P < 0.01, ***P < 0.001.red in supernatants of re-stimulated splenocytes (A) or by ELISPOT assay (B). Data
, **P  < 0.01.
in BAL remained constant in all groups and therefore their absolute
number simultaneously decreased.
5. Conclusions
Only recently, skin immunization has been put into the focus of
intense research due to increasing knowledge about the immuno-
logical functions of various skin resident cell types and their
complex interplay thus contributing to innate as well as adap-
tive immunity [40]. Although one has to keep in mind that murine
skin differs from humans not only in thickness but also in cellular
composition [41] and TLR distribution [40], remarkable similarities
in the functionality of the skin DC network exist [42]. Allergen-
speciﬁc immunotherapy via the skin has been re-visited as an
attractive alternative to current therapeutic practices. Although
recent clinical trials [16,17] and pre-clinical data from our own
group [43] have shown safety and therapeutic efﬁcacy of unad-
juvanted epicutaneous or transcutaneous immunotherapy, in this
work we  demonstrate that on a naïve background, TCI with allergen
can potentially induce allergic sensitization or exacerbate subse-
quently acquired allergic disease. In this context, application of
poorly deﬁned extracts containing allergenic components against
which a patient may  still be naïve, has to be considered with
caution. In our current work, we  demonstrate that co-application
of CpG can increase the safety of the therapy by abrogating the
TH2 polarizing potential of skin immunization. In a clinical study,
house dust mite allergen adjuvanted with CpG ODN packaged into
virus-like particles was used for SCIT and found to be safe and
well tolerated [44]. Although we  also observed no CpG-associated
side effects, future studies will be needed to identify adjuvants
for epi/transcutaneous administration with an optimal risk/beneﬁt
ratio.
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